Clinical Trials
12 trialsNCT06541314 2024-11-27
Fluzoparib Neoadjuvant Therapy for Ovarian Cancer
Qilu Hospital of Shandong University
Phase 2 Unknown
NCT05223582 2023-12-08
Fluzoparib and Abiraterone in the preSurgery Treatment of Prostate Cancer: FAST Trial
Fudan University
Phase 2 Unknown
NCT06161272 2023-12-07
Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi
Guangxi Medical University
Phase 2 Unknown
NCT06055166 2023-09-26
A Clinical Study of Chemoradiotherapy Sequential Fluzoparib in Pan-solid Tumors
Chongqing University Cancer Hospital
Phase 2 Unknown
NCT05585281 2023-07-28
A Study of Fluzoparib Combined With QL1101 Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
Liaoning Cancer Hospital & Institute
Phase 2 Unknown
NCT05932264 2023-07-06
Apatinib and Fluzoparib With or Without Adebrelimab in Previously-treated TP53-mutant Advanced Non-small Cell Lung Cancer
Sun Yat-sen University
Phase 2 Unknown
NCT05732129 2023-02-24
The Efficacy and Safety of Fluzoparib Plus Irinotecan as Second-line Treatment in Patients With Homologous Recombination Deficiency (HRD) Metastatic Colorectal Cancer.
Fudan University
Phase 2 Unknown
NCT04355858 2022-07-26
MULAN
Fudan University
Phase 2 Unknown
NCT05349409 2022-06-30
A Trial of the Combination of SHR-A1811 and Fluzoparib in HER2-Expressing Cancers
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 2 Unknown
NCT04978012 2022-06-07
Fluzoparib and Camrelizumab in Treating Patients With R/M NPC That Progressed After First-line Chemotherapy
Fudan University
Phase 2 Unknown
NCT05170594 2021-12-28
A Study of Bevacizumab Combined With Fluzoparib/Chemotherapy or Fluzoparib in the Treatment of Ovarian Cancer
The Second Affiliated Hospital of Shandong First Medical University
Phase 2 Unknown
NCT04828395 2021-05-11
F&C
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown